Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 08566021 approvals14 trials

Chabiotech Co.,Ltd.

Official website

Cord blood storage and cell therapy company that has expanded into global CDMO manufacturing and overseas medical network services.

As of 2026-10-08, Chabiotech Co.,Ltd. has 21 Korean MFDS device approvals, 5 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2002 and listed on KOSDAQ in 2005, Chabiotech is a biotech company built around cord blood banking, stem cell research, and cell therapy development. It also offers anti-aging services and consulting drawing on this expertise, while its subsidiaries run a pharmaceuticals, cosmetics, and cosmetic-ingredients product business alongside a global CDMO business and overseas medical network expansion. On a consolidated basis, 2025 revenue was split 58.65% from medical services such as overseas medical network expansion, 9.61% from product sales including pharmaceuticals and cosmetics, and 31.74% from other businesses including the global CDMO operation.

Products & technology

  • Cord blood bankingCord blood storage service
  • Stem cell research and cell therapy developmentStem cell research and cell therapy development
  • Anti-aging services and consultingAnti-aging related service and consulting leveraging accumulated know-how
  • Medical services (overseas medical network)Overseas medical network expansion and related services
  • Product sales (pharmaceuticals/cosmetics/cosmetic ingredients)Sale of pharmaceuticals, cosmetics, and cosmetic ingredients
  • Global CDMO businessGlobal CDMO business and other service businesses via subsidiaries

Regulatory approvals

data.go.kr

21 Korean MFDS device approvals · 2010–2024

  • MFDSSubsidiary: (주)차메디텍Dressing, fluid-impermeable film2024-11-27
    Product approval · Class 2제인 24-1077 호
  • MFDSSubsidiary: (주)차메디텍Graft/prosthesis2024-04-17
    Product approval · Class 4제허 24-264 호
  • MFDSSubsidiary: (주)차메디텍Graft/prosthesis2024-02-26
    Product approval · Class 4제허 24-147 호
  • MFDSSubsidiary: (주)차메디텍Graft/prosthesis, biomaterial2022-03-18
    Product approval · Class 4제허 22-195 호
  • MFDSSubsidiary: (주)차메디텍Graft/prosthesis, biomaterial2022-01-24
    Product approval · Class 4제허 22-51 호
  • MFDSSubsidiary: (주)차메디텍Graft/prosthesis, biomaterial2021-05-24
    Product approval · Class 4제허 21-403 호
  • MFDSSubsidiary: (주)차메디텍Graft/prosthesis, biomaterial2020-05-04
    Product approval · Class 4제허 20-344 호
  • MFDSSubsidiary: (주)차메디텍Graft/prosthesis, biomaterial2018-10-11
    Product approval · Class 4제허 18-676 호
  • MFDSSubsidiary: (주)차메디텍Graft/prosthesis, biomaterial2018-09-19
    Product approval · Class 4제허 18-640 호
  • MFDSSubsidiary: (주)차메디텍Graft/prosthesis, biomaterial2018-08-08
    Product approval · Class 4제허 18-568 호
  • MFDSSubsidiary: (주)차메디텍Fat separator, filter2018-05-24
    Product approval · Class 3제허 18-375 호
  • MFDSSubsidiary: (주)차메디텍Graft/prosthesis, biomaterial2016-12-05
    Product approval · Class 4제허 16-922 호
Show 9 more
  • MFDSSubsidiary: (주)차메디텍Graft/prosthesis, biomaterial2016-08-04
    Product approval · Class 4제허 16-577 호
  • MFDSSubsidiary: (주)차메디텍Graft/prosthesis, biomaterial2015-12-09
    Product approval · Class 4제허 15-1654 호
  • MFDSSubsidiary: (주)차메디텍Fat separator, filterRevoked2014-08-06
    Product approval · Class 3제허 14-1447 호
  • MFDSSubsidiary: (주)차메디텍Graft/prosthesis, biomaterial2013-05-16
    Product approval · Class 4제허 13-872 호
  • MFDSSubsidiary: (주)차메디텍Graft/prosthesis, biomaterial2013-01-28
    Product approval · Class 4제허 13-283 호
  • MFDSSubsidiary: (주)차메디텍Dressing, adhesion barrier2012-12-07
    Product approval · Class 3제허 12-1583 호
  • MFDSSubsidiary: (주)차메디텍Stimulator, skin, medicine absorptionRevoked2011-09-05
    Product approval · Class 2제허 11-974 호
  • MFDSSubsidiary: (주)차메디텍Graft/prosthesis, biomaterial2010-10-01
    Product approval · Class 4제허 10-1002 호
  • MFDSSubsidiary: (주)차메디텍Dressing, adhesion barrier2010-10-01
    Product approval · Class 3제허 10-1000 호

Clinical trials

data.go.kr

14 MFDS clinical trial authorisations · 2012–2024 (Phase 1 6 · Phase 1/2a 4 · Bioequivalence 3 · Phase 2 1)

  • Phase 1CordSTEM-ST2024-05-07

    1 trial site

  • Phase 1CordSTEM-ST2022-11-09

    1 trial site

  • Phase 1CBT1012020-09-08

    1 trial site

  • Phase 1/2aCordSTEM-DD2020-09-01

    7 trial sites

  • Phase 1Cordstem-CD Kit2016-09-13

    1 trial site

  • Phase 1/2aCordSTEM-DD2016-05-03

    7 trial sites

  • Phase 1CB-AC-022015-11-11

    1 trial site

  • Bioequivalence몬테오티에프구강붕해필름5밀리그램(몬테루카스트나트륨)2014-10-15

    2 trial sites

  • Bioequivalence몬테오티에프구강붕해필름10밀리그램(몬테루카스트나트륨)2014-10-15

    2 trial sites

  • Phase 1CordSTEM-ST2014-09-11

    1 trial site

  • Phase 2PLX-PAD 주사용 현탁액2013-11-11

    8 trial sites

  • Phase 1/2aMA09-hRPE2013-10-18

    1 trial site

Show 2 more
  • Bioequivalence아리피프라졸오티에프구강붕해필름 10mg(아리피프라졸)2013-03-12

    2 trial sites

  • Phase 1/2aMA09-hRPE2012-05-21

    2 trial sites

Global clinical trials

ClinicalTrials.gov · sponsor-matched

Key disclosures

KRX KIND via OpenDART
Show 16 more events

Publications

PubMed · affiliation-matched

Patents

KIPRIS · applicant-matched
Show 144 more patents

AI reads

MAA server logs · IP-verified
59
Times AI engines pulled Chabiotech Co.,Ltd.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

0
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

59
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

6
live 0
Last 7 days
52
live 0
Last 30 days
59
live 0
All time
  • OpenAIOAI-SearchBot51
  • PerplexityPerplexityBot5
  • AnthropicClaudeBot2
  • GoogleGoogleOther1

Measured since Aug 27, 2026 · 4 AI engines · last read Oct 7, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Chabiotech Co.,Ltd. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · R&D. Send us materials and we will add them

Companies approved for the same productsBiotech & Drug Discovery

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

DongBang Medical Co., Ltd.4 shared

KOSDAQ-listed medical device maker producing disposable acupuncture needles, cupping cups, and hyaluronic acid dermal fillers.

JETEMA Co.,Ltd.4 shared

Founded 2009, listed on KOSDAQ in 2019, JETEMA develops hyaluronic acid fillers, botulinum toxin biopharmaceuticals, and lifting threads.

PharmaResearch Co., Ltd.4 shared

KOSDAQ-listed medical device company producing PDRN pharmaceuticals, HA fillers, and Rejuran-branded cosmetics.

DongKookPharmaceuticalCo.,Ltd.4 shared

KOSDAQ-listed comprehensive healthcare and pharmaceutical company behind the gum treatment Insadol and the wound-care ointment Madecassol.

BioPlus Co., Ltd3 shared

Founded in 2003 and KOSDAQ-listed in 2021, BioPlus develops HA-based bio medical devices and biopharmaceuticals using its proprietary MDM Technology platform.

Humedix Co., Ltd.3 shared

KOSDAQ-listed aesthetics and CMO company behind the Elravie/Revolax hyaluronic-acid fillers and Leedstox botulinum toxin.

BNC KOREA, Inc.3 shared

Founded and listed on the KOSDAQ in 2016, BNC Korea is a biohealthcare company specializing in HA fillers, botulinum toxin, and dermo-cosmetics.

HANS BIOMED CORPORATION2 shared

KOSDAQ-listed medical device company producing human tissue implants Bella Cell HD and SureFuse.

DONGWHA PHARM.CO.,LTD2 shared

Dongwha Pharm, founded in 1897 and KOSPI-listed in 1976, is a diversified company centered on pharmaceuticals.

DAE HWA PHARM CO., LTD2 shared

KOSDAQ-listed pharmaceutical company behind the world's first oral paclitaxel Liporaxel (DHP107) and the Amalian dermal filler.

Medy-Tox Inc.2 shared

Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.

CAREGEN CO.,LTD.2 shared

CAREGEN develops peptide-based cosmeceuticals sold in 130 countries and ophthalmic drug candidates CG-P5 and CG-T1.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition